Korean J Intern Med.  2020 May;35(3):498-513. 10.3904/kjim.2020.105.

Angiotensin receptor-neprilysin inhibitor for the treatment of heart failure: a review of recent evidence

  • 1Division of Cardiology, Hyllym University Sacred Heart Hospital, Hallym University College of Medicine, Anyang, Korea
  • 2Division of Cardiology, Department of Internal Medicine, Gil Medical Center, Gachon University College of Medicine, Incheon, Korea


Heart failure (HF) is a growing health concern in aging societies worldwide. Sacubitril/valsartan is changing the real-world treatment in the whole spectrum of HF. The beginning was the PARADIGM-HF trial published in 2014, which demonstrated the beneficial effects of inhibiting natriuretic peptide breakdown in combination with hindering the renin-angiotensin system in HF patients with a reduced ejection fraction. Subsequent large-scale randomized trials have evaluated angiotensin receptor-neprilysin inhibitor in HF patients with acute decompensation or with preserved ejection fraction. The post hoc analyses are being conducted as well. This review summarizes the recent evidence of sacubitril/ valsartan regarding patient-centered outcomes, based on randomized controlled trials and their associated studies.


Heart failure; Angiotensin receptor inhibitor; Neprilysin
Full Text Links
  • KJIM
export Copy
  • Twitter
  • Facebook
Similar articles
    DB Error: unknown error